# Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma

> **NCT03600467** · PHASE2 · TERMINATED · sponsor: **St Vincent's Hospital, Sydney** · enrollment: 4 (actual)

## Conditions studied

- Solid Tumor
- Androgen Receptor Gene Overexpression

## Interventions

- **DRUG:** SEVI-D (Seviteronel in combination with dexamthasone)

## Key facts

- **NCT ID:** NCT03600467
- **Lead sponsor:** St Vincent's Hospital, Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-13
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor
- **Last updated:** 2021-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600467, "Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03600467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*